GEORGIA MEDICAID FEE-FOR-SERVICE ASTHMA and COPD AGENTS PA SUMMARY



Similar documents
Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources

Stacie L. Penkova, PharmD, MHSA, BCPS Clinical Pharmacy Manager Critical Care Pharmacy Specialist Drug Information Coordinator Pharmacology Summit

AECOPD: Management and Prevention

Glucocorticoids, Inhaled Therapeutic Class Review (TCR)

Living Well With COPD Chronic Bronchitis and Emphysema

Asthma & COPD Medication List

COPD. (Chronic Obstructive Pulmonary Disease) (Emphysema) (Chronic Bronchitis) Education For Our Community

AETNA BETTER HEALTH Prior Authorization guidelines for Step Therapy

Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines.

medicineupdate to find out more about this medicine

YOU VE BEEN REFERRED TO AN ASTHMA SPECIALIST...

Financial Disclosure. Pharmacy Technician Objectives: Definition: Pediatric Asthma Incidence, Pathogenesis, Severity and Treatment

Living Well With COPD Chronic Bronchitis and Emphysema

Is Albuterol Sulfate Inhalation Aerosol A Steroid

Kortverk. betaagonist. Grönmarkerat är rekommenderat i första hand vid KOL resp astma för vuxna och barn >7år. Antikolinergika.

RSPT 1410 Common Respiratory Drugs

RESPIRATORY MEDICATIONS

5. Aerosol Drug Delivery Devices: Pressurized Metered-Dose Inhalers

Medications. Patient Education Pulmonary Rehabilitation. A guide to medications for Chronic Obstructive Pulmonary Disease (COPD) Introduction

Understanding COPD. An educational health series from

COPD PROTOCOL CELLO. Leiden

EMS Information Bulletin- #060

Chronic obstructive pulmonary disease (COPD)

Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age

MEDICATION INFORMATION: CONTROLLER MEDICATIONS

CCHCS Care Guide: Asthma

Asthma, COPD and Diabetes Preferred Drug List Medications

- Canine Chronic Bronchitis cannot be cured, but can be controlled

Corticosteroids for COPD Exacerbation

COPD Prescribing Guidelines

Highlights for COPD Management

Evaluating Steroid Inhalers Used to Treat: Asthma and Chronic Lung Disease. Comparing Effectiveness, Safety, and Price

Problems With Inhaler Use: A Call for Improved Clinician and Patient Education

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma

COPD: Helping Patients Breathe Better at Home So They Can Stay at Home

Marshfield Clinic. What s inside. Health Insurance Benefit Summary April 1, March 31, Effective April 1, 2016

Doncaster & Bassetlaw Medicines Formulary

RES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP

Breathing BETTER. A handbook for people with COPD and other chronic lung conditions Intermountain Healthcare.

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim

Prevention of Acute COPD exacerbations

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma

SAVE ON MEDICAL SERVICES and PRESCRIPTION DRUGS for ongoing conditions

A Guide to Aerosol Delivery Devices

Pharmacy and Therapeutics Committee-approved Therapeutic Interchange

Office of Medical Assistance (OMA) P&T Committee Meeting Minutes

Understanding asthma. Oxford Self-help guide. Oxford

Topic: New Treatment = Better Outcome?

What to ExpEct: Your GuidE to copd

Living Well With COPD:

COPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE

COPD. What is COPD? How many people have COPD in Canada? Who gets COPD?

Global Initiative for Chronic Obstructive Lung Disease

What the pulmonary specialist should know about the new inhalation therapies

Anthem Blue Cross and Blue Shield Medicaid: Pharmacy and Therapeutics Advisory Committee meeting

Standardizing the measurement of drug exposure

Dear Provider: Sincerely,

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)

MEDICATION GUIDE. SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol

Sponsor Novartis Pharmaceuticals

Welcome COPD MANAGEMENT PROGRAM. Reproduced with permission of UofL Pulmonary s COPD Management Program

Case study 42: Managing COPD exacerbations. June Results

COPD RESOURCE PACK SECTION 11. Fife Integrated COPD Care Pathways

I. UNIFORM FORMULARY REVIEW PROCESS

Critical Care Insulin Infusion Protocol Critical Care Intensivist Admission Order Set Critical Care Pressors/Inotropes Infusion Protocol Critical

Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS

4 Pharmacological management

Medicare C/D Medical Coverage Policy

RESPIRATORY PHARMACOLOGY

Medications for COPD: A Review of Effectiveness

The. Treating patients with COPD with medications

Preferred Drug List Updates Effective: Jan. 1, 2016

Respiratory Therapy Self Assessment

PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE MEETING

Post-market review of COPD medicines. Joint submission from Lung Foundation Australia (LFA) and Thoracic Society of Australia and New Zealand (TSANZ)

The patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.

Transcription:

GEORGIA MEDICAID FEE-FOR-SERVICE ASTHMA and COPD AGENTS PA SUMMARY Preferred Anticholinergics and Combinations Atrovent HFA (ipratropium) Combivent Respimat (ipratropium/albuterol) Ipratropium neb inhalation solution generic Ipratropium/albuterol neb inhalation solution generic Spiriva Handihaler/Respimat (tiotropium) Beta Agonists (Sympathomimetics) Albuterol neb inhalation solution 0.083% (2.5mg/3mL), 0.5% (5mg/mL) generic Albuterol syrup and extended-release tablets generic Brovana (arformoterol neb inhalation solution) Metaproterenol generic Proventil HFA (albuterol) Serevent Diskus (salmeterol) Terbutaline generic Non-Preferred Anoro Ellipta (umeclidinium/vilanterol) Incruse Ellipta (umeclidinium) Seebri Neohaler (glycopyrrolate) Stiolto Respimat (tiotropium/olodaterol) Tudorza Pressair (aclidinium) Utibron Neohaler (glycopyrrolate/indacaterol) Albuterol neb inhalation solution 0.021% (0.63 mg/3 ml), 0.042% (1.25 mg/3 ml) generic Albuterol tablets generic Arcapta Neohaler (indacaterol) Levalbuterol neb inhalation solution generic Perforomist (formoterol neb inhalation solution) ProAir HFA/Respiclick (albuterol) Striverdi Respimat (olodaterol) Ventolin HFA (albuterol) Xopenex (levalbuterol neb inhalation solution) Xopenex HFA (levalbuterol) Inhaled Corticosteroids Aerospan (flunisolide) Asmanex Twisthaler (mometasone) Flovent Diskus/HFA (fluticasone propionate) Pulmicort Respules Suspension (budesonide neb suspension for inhalation) Pulmicort Flexhaler (budesonide) Qvar (beclomethasone) Inhaled Corticosteroid Combinations Advair Diskus (fluticasone/salmeterol) Symbicort (budesonide/formoterol) Methylxanthines Elixophyllin (theophylline elixir) Theophylline solution and tablets generic Theophylline CR/ER tablets generic Theo-24 (theophylline ER capsules) Phosphodiesterase-4 Inhibitors n/a Alvesco (ciclesonide) Arnuity Ellipta (fluticasone furoate) Asmanex HFA (mometasone) Budesonide neb suspension for inhalation generic Advair HFA (fluticasone/salmeterol) Breo Ellipta (fluticasone/vilanterol) Dulera (mometasone/formoterol) Lufyllin (dyphylline) Theophylline elixir generic Daliresp (roflumilast) LENGTH OF AUTHORIZATION: 1 Year

NOTES: Asmanex Twisthaler 110 mcg/inh does not require PA for members 11 years of age or younger. Xopenex Inhalation Solution does not require PA for members 8 years of age or younger. PA is required for all ages for Xopenex HFA and levalbuterol neb inhalation solution generic. If levalbuterol inhalation solution generic is approved, the PA will be issued for brand Xopenex. PA CRITERIA: Anoro Ellipta and Utibron Neohaler Approvable for members with a diagnosis of chronic obstructive pulmonary disease (COPD) who have experienced ineffectiveness, allergies, contraindications, drug-drug interactions, or intolerable side effects to Spiriva Handihaler and Serevent taken together. Incruse Ellipta, Seebri Neohaler and Tudorza Pressair ineffectiveness, allergies, contraindications, drug-drug interactions, or intolerable side effects to Spiriva. Stiolto Respimat ineffectiveness with Spiriva and Serevent taken together or have allergies, contraindications, drug-drug interactions or intolerable side effects to Serevent. Albuterol Neb Inhalation Solution 0.021% (0.63 mg/3ml), 0.042% (1.25 mg/3ml) Generic Approvable for members who have experienced ineffectiveness or intolerable side effects to albuterol neb inhalation solution 0.5% or 0.083%. Levalbuterol Neb Inhalation Solution Generic Member must who have experienced ineffectiveness or intolerable side effects to albuterol neb inhalation solution 0.5% or 0.083% brand Xopenex is not appropriate for the member. Xopenex Does not require prior authorization for members less than 9 years of age. Approvable for members 9 years of age and older who have experienced ineffectiveness or intolerable side effects to albuterol neb inhalation solution 0.5% or 0.083%. Albuterol Tablets Generic the preferred products, generic albuterol syrup and extended-release tablets, are not appropriate for the member.

Arcapta Neohaler and Striverdi Respimat Approvable for members with COPD who have experienced ineffectiveness, allergies, contraindications, drug-drug interactions, or intolerable side effects to Serevent. Perforomist ineffectiveness or intolerable side effects to Brovana. ProAir HFA, ProAir Respiclick and Ventolin HFA that the preferred product, Proventil HFA, is not appropriate for the member. Xopenex HFA Approvable for members who must have experienced ineffectiveness or intolerable side effects to Proventil HFA. Alvesco Approvable for members who have experienced ineffectiveness, allergies, contraindications, drug-drug interactions, or intolerable side effects to at least two preferred inhaled corticosteroids. Arnuity Ellipta the preferred products, Flovent Diskus and Flovent HFA as well as at least one other preferred inhaled corticosteroid, are not appropriate for the member. Asmanex HFA the preferred products, Asmanex Twisthaler and at least one other preferred inhaled corticosteroid, are not appropriate for the member. Asmanex Twisthaler 110 mcg/inh Does not require prior authorization for members less than 12 years of age. For members 12 years of age or older, prescriber must submit a written letter of medical necessity stating the reasons Asmanex Twisthaler 220 mcg/inh is not appropriate for the member. Budesonide Neb Suspension for Inhalation Generic Member must require the use of a nebulizer to administer an inhaled corticosteroid the preferred product, brand Pulmicort Respules, is not appropriate for the member. Advair HFA Approvable for members less than 12 years of age who are not able to inhale a powder formulation due to age, tracheostomy (trach) tube or mental or physical disabilities. Approvable for members 12 years of age or older who are not able to inhale a powder formulation due to tracheostomy (trach) tube or mental or physical disabilities and who have experienced ineffectiveness, allergies, contraindications, drug-drug interactions or intolerable side effects to Symbicort.

Approvable for members 12 years of age or older who are able inhale a powder formulation and have experienced ineffectiveness with Advair Diskus and have experience ineffectiveness, allergies, contraindications, drug-drug interactions or intolerable side effects to Symbicort. Breo Ellipta ineffectiveness, allergies, contraindications, drug-drug interactions, or intolerable side effects to Advair Diskus and Symbicort. Dulera Approvable for members less than 12 years of age who are not able to inhale a powder formulation due to age, tracheostomy (trach) tube or mental or physical disabilities. Approvable for members 12 years of age or older who are not able to inhale a powder formulation due to tracheostomy (trach) tube or mental or physical disabilities and who have experienced ineffectiveness with Symbicort or who have allergies, contraindications, drug-drug interactions or intolerable side effects to budesonide. Approvable for members 12 years of age or older who are able inhale a powder formulation and have experienced ineffectiveness with Advair Diskus and Symbicort or have allergies, contraindications, drug-drug interactions or intolerable side effects to Advair Diskus and budesonide. Lufyllin Approvable for a diagnosis of acute bronchial asthma or reversible bronchospasm associated with chronic bronchitis or emphysema (COPD) Approvable for members who have experienced ineffectiveness, allergies, contraindications, drug-drug interactions, intolerable side effects to theophylline. Daliresp Approvable for members 18 years of age and older with a diagnosis of severe COPD associated with chronic bronchitis Faxed documentation of FEV1 less than <50% of predicted and member is required and the member is currently on long-acting bronchodilator therapy OR Member has had at least 2 COPD exacerbations requiring administration of systemic steroids and/or antibiotics or requiring hospitalization in the past 12 months and member must have used a long-acting bronchodilator therapy within the past 12 months and be currently on long-acting bronchodilator therapy. EXCEPTIONS: Exceptions to these conditions of coverage are considered through the prior authorization process. The Prior Authorization process may be initiated by calling OptumRx at 1-866-525-5827.

PREFERRED DRUG LIST: For online access to the Preferred Drug List (PDL), please go to http://dch.georgia.gov/preferred-drug-lists. PA and APPEAL PROCESS: For online access to the PA process, please go to http://dch.georgia.gov/priorauthorization-process-and-criteria and click on Prior Authorization (PA) Request Process Guide. QUANTITY LEVEL LIMITATIONS: For online access to the Quantity Level Limits (QLL), please go to https://www.mmis.georgia.gov/portal, highlight Provider Information and click on Provider Manuals. Scroll to the page with Pharmacy Services and select that manual.